Sun Pharmaceutical Industries Limited
NSE: SUNPHARMA BSE: SUNPHARMA
NSE
1,679.20
-3.90 (-0.23%)
Prev Close
1683.1
Open Price
1685
Volume
2,500,031
Today Low / High
1669 / 1689
52 WK Low / High
1460.9 / 1960.35
Range
1,595 - 1,763
BSE
1,679.95
-3.30 (-0.20%)
Prev Close
1683.25
Open Price
1689.95
Volume
46,947
Today Low / High
1669.2 / 1689.95
52 WK Low / High
1461.4 / 1960.2
Range
1,596 - 1,764
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 1679.2 (target range: 1,595 - 1,763), reflecting a change of -3.9 (-0.23172%). On the BSE, it is listed at 1679.95 (target range: 1,596 - 1,764), showing a change of -3.3 (-0.19605%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
06 Jun
1,685.00
-0.34%
05 Jun
1,662.00
1.27%
04 Jun
1,656.00
0.54%
03 Jun
1,695.00
-1.62%
02 Jun
1,679.00
-0.26%
30 May
1,702.00
-1.43%
29 May
1,675.00
1.48%
28 May
1,683.40
-1.01%
27 May
1,676.10
0.44%
26 May
1,693.10
-1.00%
23 May
1,658.00
1.54%
22 May
1,734.20
-0.89%
21 May
1,716.40
0.90%
20 May
1,743.80
-2.06%
19 May
1,745.00
-0.85%
16 May
1,740.00
-0.29%
15 May
1,701.10
2.29%
14 May
1,702.00
0.36%
13 May
1,711.00
-0.64%
12 May
1,695.70
-0.56%
09 May
1,751.90
-0.41%
Sun Pharmaceutical Industries Limited Graph
Sun Pharmaceutical Industries Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Sun Pharmaceutical Industries Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 1,679.20, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 1,679.95 | 1,696.75 | 1,527.07 - 1,866.42 |
| 1,713.55 | 1,370.84 - 2,056.26 | ||
| 1,730.35 | 1,211.24 - 2,249.45 | ||
| Bearish Scenario | 1,679.95 | 1,663.15 | 1,496.84 - 1,829.47 |
| 1,646.35 | 1,317.08 - 1,975.62 | ||
| 1,629.55 | 1,140.69 - 2,118.42 |
Overview of Sun Pharmaceutical Industries Limited
ISIN
INE044A01036
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
2,720,780
Market Cap
4,028,870,976,000
Last Dividend
15.5
Official Website
IPO Date
1996-01-01
DCF Diff
-741.29
DCF
2,420
Financial Ratios Every Investor Needs
Stock Dividend of SUNPHARMA
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-07-07 | July 07, 25 | 5.5 | 5.5 | 2025-07-07 | 2025-08-08 | |
| 2025-02-06 | February 06, 25 | 10.5 | 10.5 | 2025-02-06 | 2025-02-20 | |
| 2024-07-12 | July 12, 24 | 5 | 5 | 2024-07-12 | 2024-08-16 | |
| 2024-02-09 | February 09, 24 | 8.5 | 8.5 | 2024-02-09 | 2024-02-23 | |
| 2023-07-28 | July 28, 23 | 4 | 4 | 2023-07-28 | 2023-09-08 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 47,758.45 Cr | 24,812.11 Cr | 22,946.34 Cr | 0.4805 | 3,127.70 Cr | 3,437.14 Cr | 10,468.18 Cr | 9,576.38 Cr | 39.91 | 13,836.33 Cr | 0.2005 |
| 2023-03-31 | 43,278.87 Cr | 10,662.16 Cr | 32,616.71 Cr | 0.7536 | 2,307.72 Cr | 2,818.46 Cr | 9,304.75 Cr | 8,473.58 Cr | 35.32 | 12,084.93 Cr | 0.1958 |
| 2022-03-31 | 38,426.42 Cr | 11,707.65 Cr | 26,718.77 Cr | 0.6953 | 2,132.51 Cr | 2,186.83 Cr | 8,147.17 Cr | 3,272.73 Cr | 13.64 | 6,699.65 Cr | 0.0852 |
| 2021-03-31 | 33,139.18 Cr | 9,885.42 Cr | 23,253.76 Cr | 0.7017 | 2,102.82 Cr | 2,385.26 Cr | 6,427.62 Cr | 2,903.82 Cr | 12.10 | 4,998.62 Cr | 0.0876 |
| 2020-03-31 | 32,325.17 Cr | 10,471.27 Cr | 21,853.90 Cr | 0.6761 | 1,925.17 Cr | 2,228.21 Cr | 4,947.77 Cr | 3,764.93 Cr | 15.69 | 7,312.90 Cr | 0.1165 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 9,285.65 Cr | 85,462.88 Cr | 18,356.91 Cr | 63,666.7500 Cr | 3,273.67 Cr | -6,011.98 Cr | 10,294.89 Cr | 11,300.05 Cr | 126.54 Cr | 489.37 Cr | 6,441.23 Cr | 16,984.4000 Cr |
| 2023-03-31 | 4,623.73 Cr | 80,743.59 Cr | 21,428.12 Cr | 55,995.3800 Cr | 6,889.66 Cr | 2,265.93 Cr | 10,513.05 Cr | 11,353.73 Cr | 7,256.18 Cr | 343.53 Cr | 5,457.48 Cr | 19,906.3800 Cr |
| 2022-03-31 | 4,508.25 Cr | 69,799.87 Cr | 18,733.76 Cr | 48,011.2200 Cr | 1,290.30 Cr | -3,217.95 Cr | 8,996.81 Cr | 11,168.89 Cr | 11,402.24 Cr | 618.75 Cr | 4,959.21 Cr | 17,200.5500 Cr |
| 2021-03-31 | 6,273.03 Cr | 67,666.73 Cr | 18,186.90 Cr | 46,462.7800 Cr | 3,868.58 Cr | -2,404.45 Cr | 8,997.02 Cr | 11,171.51 Cr | 8,687.82 Cr | 718.55 Cr | 6,482.39 Cr | 16,145.6300 Cr |
| 2020-03-31 | 5,676.61 Cr | 68,252.46 Cr | 19,127.77 Cr | 45,264.4500 Cr | 8,314.88 Cr | 2,638.27 Cr | 7,874.99 Cr | 11,226.34 Cr | 4,904.85 Cr | 759.27 Cr | 5,245.75 Cr | 15,706.4300 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 12,134.9800 Cr | -690.2000 Cr | -6,710.1600 Cr | 9,933.1700 Cr | 4,661.9200 Cr | 9,285.6500 Cr | -2,201.8100 Cr | 9,576.3800 Cr | -3,389.9300 Cr | -2,898.1700 Cr | 598.8100 Cr |
| 2023-03-31 | 4,959.3300 Cr | -7,943.6800 Cr | 2,376.0700 Cr | 2,873.7500 Cr | 115.4800 Cr | 4,623.7300 Cr | -2,085.5800 Cr | 9,408.4300 Cr | 5,129.6600 Cr | -2,518.8800 Cr | -1,202.2000 Cr |
| 2022-03-31 | 8,984.5400 Cr | -5,724.7400 Cr | -5,193.4600 Cr | 7,489.5000 Cr | -1,764.7800 Cr | 4,508.2500 Cr | -1,495.0400 Cr | 4,481.3200 Cr | -2,636.7100 Cr | -2,158.9200 Cr | 306.9500 Cr |
| 2021-03-31 | 6,170.3700 Cr | 536.2200 Cr | -5,980.4800 Cr | 5,000.2400 Cr | 596.4200 Cr | 6,273.0300 Cr | -1,170.1300 Cr | 2,799.3700 Cr | -4,371.8500 Cr | -1,559.4700 Cr | -1,080.2900 Cr |
| 2020-03-31 | 6,554.7700 Cr | -2,588.8400 Cr | -5,715.1400 Cr | 5,012.7700 Cr | -1,385.6900 Cr | 5,676.6100 Cr | -1,542.0000 Cr | 5,009.5900 Cr | -3,122.9900 Cr | -1,662.6400 Cr | 256.7700 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 13,436.94 Cr | 2,740.54 Cr | 10,696.40 Cr | 0.7960 | 3,561.81 Cr | 2,903.38 Cr | 12.10 | 4,158.47 Cr | 0.2161 |
| 2024-09-30 | 13,291.39 Cr | 5,797.81 Cr | 7,493.58 Cr | 0.5638 | 3,184.96 Cr | 3,040.16 Cr | 12.70 | 4,292.96 Cr | 0.2287 |
| 2024-06-30 | 12,652.75 Cr | 5,785.18 Cr | 6,867.57 Cr | 0.5428 | 3,002.94 Cr | 2,835.62 Cr | 11.82 | 4,140.17 Cr | 0.2241 |
| 2024-03-31 | 11,982.90 Cr | 5,330.11 Cr | 6,652.79 Cr | 0.5552 | 2,441.17 Cr | 2,654.58 Cr | 11.10 | 3,539.45 Cr | 0.2215 |
| 2023-12-31 | 12,156.86 Cr | 2,736.94 Cr | 9,419.92 Cr | 0.7749 | 3,104.89 Cr | 2,523.75 Cr | 10.52 | 3,657.22 Cr | 0.2076 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 8,012.54 Cr | 12,742.83 Cr | 20,755.37 Cr | 12,989.39 Cr | 9,935.65 Cr | 46,105.45 Cr | 11,248.33 Cr | 88,115.66 Cr | 18,736.01 Cr |
| 2024-06-30 | -19,090.06 Cr | 38,180.12 Cr | 19,090.06 Cr | 0.00 Cr | 0.00 Cr | 19,090.06 Cr | 0.00 Cr | 0.00 Cr | -67,105.97 Cr |
| 2024-03-31 | 10,520.68 Cr | 8,584.54 Cr | 19,105.22 Cr | 11,260.24 Cr | 9,868.29 Cr | 43,433.11 Cr | 11,300.05 Cr | 85,462.88 Cr | 18,356.91 Cr |
| 2023-12-31 | -14,833.25 Cr | 29,666.50 Cr | 14,833.25 Cr | 0.00 Cr | 0.00 Cr | 14,833.25 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-09-30 | 5,403.10 Cr | 10,364.24 Cr | 15,767.34 Cr | 11,302.65 Cr | 9,956.41 Cr | 39,353.80 Cr | 11,118.54 Cr | 79,441.16 Cr | 16,244.28 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-06-30 | 2,835.62 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 2,654.58 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | 2,523.75 Cr | 1,244.28 Cr | 0.00 Cr | 0.00 Cr | 1,244.28 Cr | 8,466.29 Cr | 7,222.01 Cr | 0.00 Cr | 1,244.28 Cr |
| 2023-09-30 | 2,375.51 Cr | 1,265.64 Cr | 0.00 Cr | 0.00 Cr | 1,265.64 Cr | 7,222.01 Cr | 5,956.37 Cr | 0.00 Cr | 1,265.64 Cr |
| 2023-06-30 | 2,022.54 Cr | 1,302.64 Cr | 0.00 Cr | 0.00 Cr | 1,302.64 Cr | 5,939.26 Cr | 4,636.62 Cr | 0.00 Cr | 1,302.64 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2013-07-29 | July 29, 13 | 2:1 |
| 2010-11-25 | November 25, 10 | 5:1 |
| 2004-05-27 | May 27, 04 | 2:1 |
| 2003-01-13 | January 13, 03 | 2:1 |
| 2000-03-08 | March 08, 00 | 3:1 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,679.20 | ₹4,028,870,976,000.00 | ₹2,500,031.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,544.50 | ₹1,737,361,870,500.00 | ₹361,018.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,320.90 | ₹1,100,458,988,118.00 | ₹2,158,463.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,154.30 | ₹1,067,557,063,500.00 | ₹86,576.00 |
| Mankind Pharma Limited | MANKIND | ₹2,352.40 | ₹970,767,378,020.00 | ₹353,197.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹960.15 | ₹966,131,734,500.00 | ₹810,089.00 |
| Lupin Limited | LUPIN | ₹1,999.60 | ₹913,207,322,000.00 | ₹1,289,535.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,161.10 | ₹674,369,202,200.00 | ₹392,642.00 |
| Alkem Laboratories Limited | ALKEM | ₹4,862.50 | ₹581,384,812,500.00 | ₹181,782.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,590.20 | ₹448,756,030,200.00 | ₹940,265.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Cohance Lifesciences Limited | COHANCE | ₹1,055.10 | ₹403,646,450,141.00 | ₹209,681.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,370.90 | ₹347,802,813,600.00 | ₹594,702.00 |
| Laurus Labs Limited | LAURUSLABS | ₹642.05 | ₹346,227,388,650.00 | ₹1,658,718.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,571.30 | ₹321,186,225,600.00 | ₹84,218.00 |
| Piramal Enterprises Limited | PEL | ₹1,173.70 | ₹266,051,968,600.00 | ₹1,087,297.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,702.30 | ₹265,322,180,300.00 | ₹62,791.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,790.00 | ₹244,750,000,000.00 | ₹123,199.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,505.40 | ₹244,595,886,600.00 | ₹803,276.00 |
| Eris Lifesciences Limited | ERIS | ₹1,638.30 | ₹223,111,885,500.00 | ₹55,563.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹987.60 | ₹194,125,618,800.00 | ₹40,498.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,140.00 | ₹181,580,340,000.00 | ₹116,733.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,030.00 | ₹167,173,597,000.00 | ₹539,376.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,093.30 | ₹159,115,291,610.00 | ₹64,315.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹858.30 | ₹153,730,113,000.00 | ₹354,578.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹529.95 | ₹128,536,192,800.00 | ₹485,798.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,560.50 | ₹92,300,963,700.00 | ₹8,096.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹914.45 | ₹89,424,888,505.00 | ₹310,698.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹909.25 | ₹82,409,528,235.00 | ₹242,116.00 |
| Strides Pharma Science Limited | STAR | ₹782.30 | ₹72,098,880,210.00 | ₹430,298.00 |
| FDC Limited | FDC | ₹429.20 | ₹69,878,052,000.00 | ₹308,089.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹165.55 | ₹53,724,617,100.00 | ₹2,347,837.00 |
| Innova Captab Limited | INNOVACAP | ₹889.10 | ₹50,878,685,263.00 | ₹72,505.00 |
| Suven Life Sciences Limited | SUVEN | ₹221.19 | ₹48,235,788,060.00 | ₹1,475,325.00 |
| Sequent Scientific Limited | SEQUENT | ₹187.85 | ₹47,019,230,700.00 | ₹442,806.00 |
| Hikal Limited | HIKAL | ₹372.35 | ₹45,911,127,350.00 | ₹154,610.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹462.15 | ₹42,180,430,500.00 | ₹112,178.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹592.90 | ₹41,743,598,820.00 | ₹18,878.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹368.10 | ₹36,912,331,800.00 | ₹50,918.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹718.15 | ₹36,423,921,665.00 | ₹149,821.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,141.70 | ₹35,421,576,300.00 | ₹12,390.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹64.12 | ₹35,134,810,480.00 | ₹2,840,731.00 |
| Alembic Limited | ALEMBICLTD | ₹112.07 | ₹28,777,558,628.00 | ₹591,652.00 |
| IOL Chemicals and Pharmaceuticals Limited | IOLCP | ₹88.74 | ₹26,047,585,980.00 | ₹1,118,303.00 |
| Indoco Remedies Limited | INDOCO | ₹275.10 | ₹25,377,397,290.00 | ₹25,198.00 |
Key Executives
Vice President, Head of Investor Relations & Strategic Projects
Dr. Abhishek Sharma
Gender: Not Specified
Year Born:
Company Secretary & Compliance Officer
Mr. Anoop Deshpande
Gender: male
Year Born:
Chief Human Resources Officer
Mr. Suresh Kumar Rai
Gender: male
Year Born:
Chief Operating Officer, Head of Global Generics R&D, Business Devp., and Whole Time Director
Mr. Aalok Dilip Shanghvi
Gender: male
Year Born: 1984
Chief Financial Officer
Mr. C. S. Muralidharan ICWA, M.Com
Gender: male
Year Born: 1963
Director of Corporate Development
Mr. Kalyanasundaram Subramanian
Gender: male
Year Born: 1954
MD & Chairman of the Board
Mr. Dilip Shantilal Shanghvi
Gender: male
Year Born: 1955
Head of India Business
Mr. Kirti Wardhaman Ganorkar
Gender: male
Year Born: 1967
Chief Executive Officer of North America Business
Mr. Abhay Gandhi
Gender: male
Year Born: 1965
EVice President & Chief Information Officer
Mr. Dheeraj Prasad Sinha BE
Gender: male
Year Born: 1971
FAQs about Sun Pharmaceutical Industries Limited
Who is the CEO of the company?
The CEO is Mr. Abhay Gandhi.
What is the current market price of the stock?
The current price is ₹1,679.20.
What is the 52-week price range?
The range is ₹1460.9-1960.35.
What is the market capitalization of the company?
The market capitalization is ₹402,887.10 crores.
What is the dividend yield?
The dividend yield is 0.92%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 35.24.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Sun Pharmaceutical Industries Limited (ISIN: INE044A01036) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹402,887.10 crores and an average daily volume of 2,720,780 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹15.5.